Related Experiment Video
Updated: Feb 7, 2026

Single Liposome Measurements for the Study of Proton-Pumping Membrane Enzymes Using Electrochemistry and Fluorescent Microscopy
Published on: February 21, 2019
Significant association between the use of different proton pump inhibitors and microscopic colitis: a nationwide
Ole K Bonderup1, Gunnar L Nielsen2,3, Michael Dall4,5
1Diagnostic Centre, Regional Hospital Silkeborg, and University Research Clinic for Innovative Patient Pathways, Aarhus University, Aarhus, Denmark.
Background:
Microscopic colitis causes chronic watery diarrhoea and has previously been associated with the use of proton pump inhibitors.
Aim:
To explore the association between proton pump inhibitor use and microscopic colitis, including its dependency on timing, dose and choice of proton pump inhibitor.
Methods:
Within a 10-year period, we identified 10 652 patients with a first-time diagnosis of microscopic colitis, including 6254 (59%) with collagenous colitis and 4398 (41%) with lymphocytic colitis. All microscopic colitis cases were histologically confirmed in the Danish Pathology Register. Information on proton pump inhibitor use was obtained from the Danish Prescription Register. In this case-control study, we estimated the adjusted odds ratios (aOR) for the association between proton pump inhibitor use and risk of microscopic colitis using conditional logistic regression while adjusting for potential confounders.
Results:
We found strong associations between current proton pump inhibitor use and both collagenous colitis (aOR 6.98; 95% CI: 6.45-7.55) and lymphocytic colitis (aOR 3.95; 95% CI: 3.60-4.33). This association was observed with all PPIs. The strongest association was with the current use of lansoprazole for both collagenous colitis (aOR 15.74; 95% CI: 14.12-17.55) and lymphocytic colitis (aOR 6.87; 95% CI: 6.00-7.86). When considering timing, ORs were highest for current use of proton pump inhibitor and lower for recent or past exposure. No clear dose-response pattern was observed.
Conclusions:
We found a strong association between microscopic colitis and ongoing use of proton pump inhibitors, especially lansoprazole.
Insights
Proton pump inhibitor (PPI) use is strongly linked to microscopic colitis, particularly collagenous and lymphocytic types. Ongoing PPI use, especially lansoprazole, shows the highest risk for developing these conditions.
Area of Science:
- Gastroenterology
- Pharmacology
Background:
- Microscopic colitis is characterized by chronic watery diarrhea.
- Previous research suggests a link between proton pump inhibitor (PPI) use and microscopic colitis.
Purpose of the Study:
- To investigate the association between PPI use and microscopic colitis.
- To examine how timing, dosage, and specific PPIs influence this association.
Main Methods:
- A case-control study involving 10,652 patients diagnosed with microscopic colitis over 10 years.
- Utilized Danish Pathology and Prescription Registers for diagnosis and PPI use data.
- Employed conditional logistic regression to calculate adjusted odds ratios (aOR).
Main Results:
- Strong associations were found between current PPI use and both collagenous colitis (aOR 6.98) and lymphocytic colitis (aOR 3.95).
- Lansoprazole showed the strongest association for both types (aOR 15.74 for collagenous, aOR 6.87 for lymphocytic).
- The risk was highest with current PPI use, decreasing with recent or past use; no clear dose-response was observed.
Conclusions:
- A significant association exists between ongoing proton pump inhibitor use and microscopic colitis.
- Current PPI users, particularly those on lansoprazole, face an elevated risk.
More Related Videos
08:58Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis
Published on: January 5, 2017
15:49Flexible Colonoscopy in Mice to Evaluate the Severity of Colitis and Colorectal Tumors Using a Validated Endoscopic Scoring System
Published on: October 16, 2013
Related Concept Videos
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
ATP Driven Pumps III: V-type Pumps
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
ATP Driven Pumps II: P-type Pumps
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...